drugset / Trial / NCT04924192
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.
Timeline
- Start
- 2021-08-18
- Primary completion
- 2022-09-27
- Completion
- 2022-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Subject | Irinotecan | Small molecule | 100 mg/m2 | Intravenous |
| Subject | TQB3616 | Small molecule | 120 mg | Oral |
| Subject | TQB3616 | Small molecule | 150 mg | Oral |
| Subject | TQB3616 | Small molecule | 180 mg | Oral |